<DOC>
	<DOCNO>NCT02018432</DOCNO>
	<brief_summary>Main adverse event Roflumilast weight loss , loss appetite , insomnia , headache , diarrhea , vomit , nausea . Although majority adverse reaction mild moderate . They occur mainly begin therapy mostly resolve continued treatment around two week accord experience clinician . These adverse event occur often Roflumilast 500 μg 250 μg , negative impact compliance patient early stage treatment . Thus , investigator aim compare drop-out rate usual dosage ( Roflumilast 500 μg daily ) dose escalation ( Roflumilast 250 μg daily 4 week escalate dose 500 μg daily ) .</brief_summary>
	<brief_title>Strategy Improve Adherence Roflumilast</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>1 . Male female old 40 year 2 . Clinical diagnosis COPD ( confirm postbronchodilator force expiratory volume 1 [ FEV1 ] /forced vital capacity [ FVC ] ratio ≤70 % ) least 4 week prior study postbronchodilator FEV1 50 % le predicted value 3 . Former smoker current smoker least 10 packyear history 4 . A history exacerbation ( scheduled/unscheduled visit primary care physician , specialist ally healthcare professional , emergency room , hospitalization due purulent sputum increase sputum , increase dyspnea ) previous year ( least one ) 5 . Chronic bronchitis ( cough sputum production least three month within two year ) 6 . Able sign write informed consent prior studyrelated procedure . 1 . COPD exacerbation respiratory infection 4 week prior baseline visit 2 . Known a1antitrypsin deficiency 3 . Need longterm oxygen therapy 4 . Moderate severe liver impairment ( ChildPugh B C ) 5 . Severe immunological disease ( e.g . HIV infection , multiple sclerosis , lupus erythematosus , etc ) 6 . Severe acute infectious disease 7 . Cancers 8 . Subjects treat immunosuppressive medicinal product ( i.e . : methotrexate , azathioprine , infliximab , etanercept , oral corticosteroid take longterm ) except shortterm systemic corticosteroid ) 9 . Latent infection tuberculosis , viral hepatitis , herpes viral infection herpes zoster 10 . Subjects congestive heart failure ( NYHA grade 3 4 ) 11 . Subjects history depression associate suicidal ideation behavior 12 . Clinically meaningful bronchiectasis 13 . Pregnancy breast feeding , Female subject childbearing potential unwilling use effective contraception 14 . Patients know hypersensitivity Roflumilast rescue medication ingredient 15 . Patients previous Roflumilast therapy within past 3 month</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>